AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Summary
- Imugene's preclinical research associated with mimotope vaccines targeting immune checkpoint inhibitors published in 'Frontiers in Immunology' journal.
- Research discovered that mimotope peptides when included in Imugene's exclusive immunotherapeutic vaccine delivery platform, produce antibodies that particularly bind to immune cells expressing the PD1 biomarker.
- Imugene seems to be advancing well on its vision to help transform cancer treatment, strongly backed by peer-reviewed research and mounting body of clinical evidence.
Clinical stage immuno-oncology player, Imugene Limited's (ASX:IMU) preclinical research associated with its mimotope vaccines targeting immune checkpoint inhibitors (ICI) has been approved and published in the eminent journal 'Frontiers in Immunology' with the title 'New Strategy Toward B Cell-Based Immunotherapy by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors'.
The publication is a detailed research of the course of action of active immunisation aimed at immune checkpoint regulator PD1. The ground-breaking research from Medical University of Vienna was carried out under the leadership of Imugene's Scientific Advisory Board (SAB) member, Professor Dr Ursula Wiedermann, along with Dr Joshua Tobias as lead author.
Key Outcomes of Preclinical Research
The research published in the journal has discovered that mimotope peptides when included in the Company's exclusive immunotherapeutic vaccine delivery platform, produce antibodies that particularly bind to immune cells expressing the PD1 biomarker.
These naturally generated antibodies inhibit a protective mechanism on cancer cells, enabling immune system to kill those cancer cells, similar to breast cancer animal models.
Imugene notified that this is the first journal report of treating cancer by teaching and encouraging the body to produce its own antibodies targeting PD1 expressing cells. Consequently, the approach signifies a paradigm shift in oncology segment.
On this new development, Imugene's MD & CEO, Leslie Chong commented:
PD1-Vaxx to Enter Phase 1 trial in 2020
The research outcomes validate and support the B cell "epitope" embodied in PD1-Vaxx, targeted to enter a Phase 1 trial in 2020.
Imugene's PD-1 targeting cancer immunotherapy, PD1-Vaxx is targeted to treat patients with small cell lung cancer and produce an anti-cancer effect similar to other immune checkpoint inhibitors and monoclonal antibodies (such as Opdivo® and Keytruda® that are transforming treatment of varied cancer forms) by interfering with PD-1/PD-L1 interaction and binding.
Recently, Imugene's Vice President of Clinical Research, Dr Anthony Good presented the clinical plan for its PD1-Vaxx at American Association for Cancer Research Virtual Annual Meeting 2020.
The primary objective of this B-cell cancer immunotherapy's phase 1 trial is to evaluate safety profile and an optimal biological dose as monotherapy and in combination with immune checkpoint inhibitors. Besides, the study also aims at measuring tolerability, immune response and efficacy.
Imugene seems to be well positioned to progress with PD1-Vaxx Phase 1 trial in 2020, backed by incredible workflow from its scientists and a highly skilled management team. The Company's robust balance sheet and capital position further strengthens the prospects for the same.
Also Read! Imugene Announced Completion of GMP manufacturing and Toxicology Studies for PD1-Vaxx
IMU closed the trading session at $0.034 on 29th May 2020.
